Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 1;10:652. doi: 10.3389/fimmu.2019.00652

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Zeng, Qiu, Chen, Liu, Liu, Liang, Zhang and Dai.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Shikonin prolongs skin allograft survival and reduces CD3⁺ T cell infiltration in skin allografts. (A) C57BL/6 mice were transplanted with a skin allograft from a BALB/C donor and treated without or with shikonin or CsA (20 mg/kg). The survival times of the skin grafts were observed (*P < 0.05 and **P < 0.01, n = 8–9). H&E (B) and immunohistochemical staining for CD3 (C) were performed 10 days post-transplantation. (D) Transplanted mice were treated with shikonin plus low doses of CsA (10 mg/kg) and/or anti-CD45RA mAb (0.1 mg) to observe the effects of the double or triple treatments on skin allograft survival (**P < 0.01, n = 8–9).